uric acid has been researched along with Idiopathic Parkinson Disease in 160 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the association between uric acid (UA) levels and vascular dementia (VaD) and Parkinson's disease dementia (PDD), a meta-analysis was conducted." | 9.41 | Uric acid levels and their association with vascular dementia and Parkinson's disease dementia: a meta-analysis. ( Cen, K; Cui, Y; Feng, X; Hou, X; Li, Q, 2023) |
| "This study aims to investigate relationship between the level of uric acid (UA) and UA/creatinine ratios (UA/Cr) to the stage of Parkinson disease (PD)." | 7.88 | Level of uric acid and uric acid/creatinine ratios in correlation with stage of Parkinson disease. ( Cao, H; Ju, KJ; Song, YQ; Tian, XY; Zhong, LL, 2018) |
| "Several epidemiologic studies have described an association between low serum uric acid (UA) and Parkinson disease (PD)." | 7.83 | Potential mechanisms for low uric acid in Parkinson disease. ( Bernhard, D; Factor, S; Jinnah, HA; Millington, D; Rosen, A; Sampat, R; Young, S, 2016) |
| "4 years of follow-up, we observed that higher serum levels of uric acid were associated with a significantly decreased risk of Parkinson disease (adjusted hazard ratio per standard deviation increase 0." | 7.73 | Serum uric acid levels and the risk of Parkinson disease. ( Breteler, MM; de Lau, LM; Hofman, A; Koudstaal, PJ, 2005) |
| "Inosine, dosed by blinded titration to increase serum urate concentrations to 7." | 7.01 | Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. ( Ahmed, A; Ainslie, M; Aldred, J; Ascherio, A; Beck, CA; Bhatti, D; Bixby, M; Blindauer, K; Bodis-Wollner, I; Bolger, P; Boyd, JT; Brodsky, M; Bwala, G; Callahan, KF; Casaceli, C; Chou, K; Christine, C; Ciccarello, J; Cloud, L; Criswell, SR; Crotty, GF; Curhan, GC; Daley, A; de Marcaida, JA; Deik, AF; Dewey, RB; Durphy, J; Espay, AJ; Fang, JY; Fitzgerald, R; Friedman, JH; Gauger, L; Gerald, A; Goetz, C; Goudreau, J; Gunzler, SA; Hauser, RA; Henchcliffe, C; Hinson, V; Houghton, DJ; Houston, E; Hung, A; Hunter, C; James, R; Jimenez-Shahed, J; Kaminski, P; Kamp, C; Keith, K; Klements, D; Kostrzebski, M; Kumar, R; Kurlan, R; LaFaver, K; Lang, A; Langhammer, A; Laroche, A; LeDoux, MS; Leehey, M; LeWitt, PA; Litvan, I; Lungu, C; Macklin, EA; Marek, K; Mari, Z; McGraw, M; McMahon, GM; Mehta, SH; Mestre, T; Morgan, JC; Mosovsky, S; Mozaffarian, D; Oakes, D; Pahwa, R; Park, A; Peterson, C; Poon, C; Pothier, L; Rabin, M; Ratel, AS; Reich, S; Rosenthal, L; Rudolph, A; Russell, D; Saint-Hilaire, M; Schiess, MC; Schneider, RB; Schwarzschild, MA; Scott, B; Serrano, C; Shah, BB; Shill, HA; Shoulson, I; Shprecher, D; Simon, DK; Simuni, T; Soileau, M; Stover, N; Suski, V; Thomas, K; Videnovic, A; Waikar, SS; Waters, C; Zauber, SE; Zhang, L, 2021) |
| "Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), currently represent major unmet medical needs." | 6.82 | Inosine in Neurodegenerative Diseases: From the Bench to the Bedside. ( Basile, MS; Bramanti, P; Mazzon, E, 2022) |
| "To explore the association between uric acid (UA) levels and vascular dementia (VaD) and Parkinson's disease dementia (PDD), a meta-analysis was conducted." | 5.41 | Uric acid levels and their association with vascular dementia and Parkinson's disease dementia: a meta-analysis. ( Cen, K; Cui, Y; Feng, X; Hou, X; Li, Q, 2023) |
| "Levodopa is the most used and effective medication for motor symptoms of Parkinson disease (PD), its long-term use is associated with the appearance of levodopa-induced dyskinesia (LID)." | 4.31 | Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease. ( Almeida, RMM; Artigas, NR; Dutra, ACL; Krimberg, JS; Monticelli, BE; Pereira, GM; Rieder, CRM; Schumacher-Schuh, AF; Soares, NM, 2023) |
| "Our present study assessed the role of serum uric acid as a putative biomarker in a prodromal PD cohort [REM Sleep Behavior disorder (RBD) and Hyposmia] followed longitudinally." | 4.31 | Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson's Disease: Longitudinal Data from the PPMI Study. ( Angelopoulou, E; Antonelou, R; Beratis, I; Bonakis, A; Bougea, A; Bregianni, M; Koros, C; Lourentzos, K; Pachi, I; Papadimitriou, D; Papageorgiou, SG; Papagiannakis, N; Prentakis, A; Simitsi, AM; Stamelou, M; Stanitsa, E; Stefanis, L; Trapali, XG, 2023) |
| "The progression rate was faster in the tremor domain than the nontremor domain before levodopa treatment." | 4.12 | Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. ( Chan, J; Goetz, CG; Luo, S; Macklin, EA; Oakes, D; Schwarzschild, MA; Simuni, T; Stebbins, GT; Zou, H, 2022) |
| "Lower serum urate concentration is associated with worsening motor function; while higher homocysteine concentration is associated with change in motor function and cognitive decline." | 3.91 | Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson's Disease. ( Burn, DJ; Duncan, GW; Johnston, F; Khoo, TK; Lawson, RA; Sleeman, I; Yarnall, AJ, 2019) |
| "This study aims to investigate relationship between the level of uric acid (UA) and UA/creatinine ratios (UA/Cr) to the stage of Parkinson disease (PD)." | 3.88 | Level of uric acid and uric acid/creatinine ratios in correlation with stage of Parkinson disease. ( Cao, H; Ju, KJ; Song, YQ; Tian, XY; Zhong, LL, 2018) |
| "Serum uric acid (UA) levels are reported to be decreased in patients with Parkinson's disease (PD) and multiple system atrophy (MSA)." | 3.85 | Serum uric acid levels in Parkinson's disease and related disorders. ( Fujita, H; Hirata, K; Miyamoto, M; Miyamoto, T; Numao, A; Sakuta, H; Suzuki, K; Watanabe, Y, 2017) |
| "Several epidemiologic studies have described an association between low serum uric acid (UA) and Parkinson disease (PD)." | 3.83 | Potential mechanisms for low uric acid in Parkinson disease. ( Bernhard, D; Factor, S; Jinnah, HA; Millington, D; Rosen, A; Sampat, R; Young, S, 2016) |
| "The aim of this study was to evaluate serum uric acid (UA) levels and serum uric acid/creatinine ratios (UA/Cr) in patients with non-tremor dominant (NTD) Parkinson's disease (PD) compared to tremor dominant (TD) PD and healthy controls (HC)." | 3.81 | Association between serum uric acid and motor subtypes of Parkinson's disease. ( Kulkantrakorn, K; Lolekha, P; Wongwan, P, 2015) |
| "This study investigated the epidemiological evidence for a protective role of high serum concentration of uric acid, for which we used gout as a proxy, in the aetiology of MS, PD or MND." | 3.81 | Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies. ( Goldacre, MJ; Pakpoor, J; Ramagopalan, SV; Seminog, OO, 2015) |
| " In ET patients, cognitive scores were correlated with serum levels of uric acid, education, tremor Rating Scale for Tremor-motor subscale score and depression levels (r = 0." | 3.80 | [Cognitive dysfuctions associated with essential tremor and Parkinson's disease]. ( Chen, J; Chen, Y; Liu, C; Mao, C; Wu, Y; Yao, J, 2014) |
| "Our population-based data provide evidence for a protective effect of gout on the risk of PD and support the purported protective role of uric acid." | 3.74 | Gout and the risk of Parkinson's disease: a cohort study. ( Choi, H; De Vera, M; Gao, X; Kopec, J; Rahman, MM; Rankin, J, 2008) |
| "4 years of follow-up, we observed that higher serum levels of uric acid were associated with a significantly decreased risk of Parkinson disease (adjusted hazard ratio per standard deviation increase 0." | 3.73 | Serum uric acid levels and the risk of Parkinson disease. ( Breteler, MM; de Lau, LM; Hofman, A; Koudstaal, PJ, 2005) |
| "Inosine, dosed by blinded titration to increase serum urate concentrations to 7." | 3.01 | Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. ( Ahmed, A; Ainslie, M; Aldred, J; Ascherio, A; Beck, CA; Bhatti, D; Bixby, M; Blindauer, K; Bodis-Wollner, I; Bolger, P; Boyd, JT; Brodsky, M; Bwala, G; Callahan, KF; Casaceli, C; Chou, K; Christine, C; Ciccarello, J; Cloud, L; Criswell, SR; Crotty, GF; Curhan, GC; Daley, A; de Marcaida, JA; Deik, AF; Dewey, RB; Durphy, J; Espay, AJ; Fang, JY; Fitzgerald, R; Friedman, JH; Gauger, L; Gerald, A; Goetz, C; Goudreau, J; Gunzler, SA; Hauser, RA; Henchcliffe, C; Hinson, V; Houghton, DJ; Houston, E; Hung, A; Hunter, C; James, R; Jimenez-Shahed, J; Kaminski, P; Kamp, C; Keith, K; Klements, D; Kostrzebski, M; Kumar, R; Kurlan, R; LaFaver, K; Lang, A; Langhammer, A; Laroche, A; LeDoux, MS; Leehey, M; LeWitt, PA; Litvan, I; Lungu, C; Macklin, EA; Marek, K; Mari, Z; McGraw, M; McMahon, GM; Mehta, SH; Mestre, T; Morgan, JC; Mosovsky, S; Mozaffarian, D; Oakes, D; Pahwa, R; Park, A; Peterson, C; Poon, C; Pothier, L; Rabin, M; Ratel, AS; Reich, S; Rosenthal, L; Rudolph, A; Russell, D; Saint-Hilaire, M; Schiess, MC; Schneider, RB; Schwarzschild, MA; Scott, B; Serrano, C; Shah, BB; Shill, HA; Shoulson, I; Shprecher, D; Simon, DK; Simuni, T; Soileau, M; Stover, N; Suski, V; Thomas, K; Videnovic, A; Waikar, SS; Waters, C; Zauber, SE; Zhang, L, 2021) |
| " An inosine dosage of 1070 (SD=501) mg/day significantly raises the urate level from 3." | 2.84 | One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan. ( Ando, R; Iwaki, H; Miyaue, N; Nagai, M; Nishikawa, N; Nomoto, M; Tada, S; Tsujii, T; Yabe, H, 2017) |
| "The global burden of Parkinson's disease (PD) has increased from 2." | 2.82 | Parkinson's Disease: Risk Factor Modification and Prevention. ( Kaas, B; Rajan, S, 2022) |
| "It is known that hyperuricemia is recognized as an independent cardiovascular risk factor." | 2.82 | [The role of hyperuricemia in the development of cognitive changes in the elderly.] ( Ariev, AL; Kunitskaya, NA, 2022) |
| "Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), currently represent major unmet medical needs." | 2.82 | Inosine in Neurodegenerative Diseases: From the Bench to the Bedside. ( Basile, MS; Bramanti, P; Mazzon, E, 2022) |
| "Numerous studies have linked Parkinson's disease (PD) with low levels of uric acid (UA)." | 2.82 | Uric Acid in Parkinson's Disease: What Is the Connection? ( Dinasarapu, AR; Jinnah, HA; Seifar, F, 2022) |
| "A total of 104 patients with Parkinson's disease were divided into two groups: those with cognitive impairment and those without." | 2.74 | [Study on uric acid and the related factors associated with cognition in the patients with Parkinson's disease]. ( Liu, CF; Luo, WF; Mao, CJ; Wang, L; Wang, LJ; Wang, XJ, 2009) |
| "Amantadine proved to be a useful and safe addition to the armamentarium when given in daily doses of 200 mg." | 2.64 | Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study. ( Barbeau, A; Botez, MI; Joubert, M; Mars, H, 1971) |
| "Hyperuricemia has been recognized as an independent cardiovascular risk factor in epidemiological studies." | 2.58 | Uric Acid and Cognitive Function in Older Individuals. ( Meschi, T; Nouvenne, A; Prati, B; Tana, C; Ticinesi, A, 2018) |
| " Rather than prompting abandonment of antioxidant strategies, these failures have raised the bar for justifying drug and dosing selections and for improving study designs to test for disease modification by antioxidants." | 2.55 | Targeting urate to reduce oxidative stress in Parkinson disease. ( Ascherio, A; Crotty, GF; Schwarzschild, MA, 2017) |
| "While the etiology and pathogenesis of Parkinson's disease (PD) is still obscure, there is evidence for lifestyle factors influencing disease risk." | 2.52 | Linking Smoking, Coffee, Urate, and Parkinson's Disease - A Role for Gut Microbiota? ( Auvinen, P; Kaakkola, S; Pekkonen, E; Scheperjans, F, 2015) |
| " A dose-response trend of serum urate to reduce PD risk was also observed involving 11 795 participants (RR=0." | 2.49 | Serum urate and the risk of Parkinson's disease: results from a meta-analysis. ( Ding, M; Guo, Y; Lin, C; Luo, W; Shen, C, 2013) |
| "The motor symptoms of Parkinson's disease (PD) are primarily due to the degeneration of the dopaminergic neurons in the nigrostriatal pathway." | 2.46 | Pathophysiological roles for purines: adenosine, caffeine and urate. ( Carta, AR; Kachroo, A; Morelli, M; Schwarzschild, MA, 2010) |
| "Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD." | 2.44 | Uric acid in Parkinson's disease. ( Schlesinger, I; Schlesinger, N, 2008) |
| "However, the pathogenesis of sleep disorders in PD patients remains unclear." | 1.91 | Low serum uric acid levels may be a potential biomarker of poor sleep quality in patients with Parkinson's disease. ( Gu, M; Lei, C; Liu, J; Xu, Z; Yang, X; Yin, K; Yin, L; Yin, W; Zhou, C; Zhu, Y, 2023) |
| "Recent developments in the field of Parkinson's Disease (PD) pathophysiology have led to a renewed interest in this field." | 1.72 | Uric acid: The role in the pathophysiology and the prediction in the diagnosis of Parkinson's disease: A Turkish-based study. ( Ari, BC; Domac, FM; Kenangil, GO; Tur, EK, 2022) |
| "Uric acid (UA) is an important endogenous antioxidant that protects against oxidative stress, yet its exact role in neurodegeneration remains unclear." | 1.72 | Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study. ( Aerqin, Q; Chen, KL; Chen, SF; Dong, Q; Huang, YY; Jia, SS; Li, Q; Ou, YN; Shen, XN; Yu, JT, 2022) |
| "Uric acid (UA) plays a protective role in Parkinson's disease (PD)." | 1.72 | Low serum uric acid levels are associated with the nonmotor symptoms and brain gray matter volume in Parkinson's disease. ( Hu, S; Huang, S; Li, M; Ma, J; Shi, X; Sun, W; Wang, Z; Zheng, J, 2022) |
| "Cardio-metabolic diseases and Parkinson's disease were more frequent in men with hypouricaemia than those without hypouricaemia." | 1.72 | Temporal trends in the prevalence and characteristics of hypouricaemia: a descriptive study of medical check-up and administrative claims data. ( Kawakami, K; Koto, R; Kuwabara, M; Sato, I; Seki, T, 2022) |
| "High uric acid (UA) levels have been shown to exert a neuroprotective effect in Parkinson's disease (PD) by inhibiting oxidative stress in the nigrostriatal pathway." | 1.56 | Gender difference in the effect of uric acid on striatal dopamine in early Parkinson's disease. ( Hwang, EJ; Kim, JS; Lee, KS; Lyoo, CH; Oh, YS; Yoo, SW, 2020) |
| "Young-onset Parkinson's disease (YOPD) is a relevant condition whose neurobiology is questioned if different from those of typical late-onset Parkinson's disease (LOPD)." | 1.56 | Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features. ( Bernardini, S; Colona, VL; Di Lazzaro, G; Mercuri, NB; Petrucci, S; Pierantozzi, M; Pisani, A; Sancesario, GM; Schirinzi, T; Stefani, A; Summa, S, 2020) |
| "Uric acid has been found to be potentially neuroprotective in Parkinson's disease (PD)." | 1.48 | Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson's disease: PALS study. ( Acharyya, S; Au, WL; Chia, NS; Huang, X; Lu, ZH; Ng, E; Ng, SY; Setiawan, F; Tan, EK; Tan, LC; Tay, KY, 2018) |
| "Uric acid has neuroprotective effect on Parkinson's disease (PD) by inhibiting oxidative damage and neuronal cell death." | 1.46 | Uric acid demonstrates neuroprotective effect on Parkinson's disease mice through Nrf2-ARE signaling pathway. ( Hao, DL; Huang, TT; Mao, LL; Wu, BN; Zhang, J, 2017) |
| "Uric acid (UA) is a natural antioxidant and iron scavenger in the human body, which has been hypothesized to exert an anti-oxidative effect in Parkinson's disease (PD)." | 1.46 | Serum uric acid levels and freezing of gait in Parkinson's disease. ( Cao, B; Hou, Y; Ou, R; Shang, H; Song, W; Wei, Q; Xu, Y; Zhao, B, 2017) |
| "Uric acid is a natural antioxidant, and it has been shown that low levels of uric acid could be a risk factor for the development of PD." | 1.43 | Low serum uric acid levels in progressive supranuclear palsy. ( Cáceres-Redondo, MT; Carballo, M; Carrillo, F; Gómez-Garre, P; Huertas-Fernández, I; Jesús, S; Mir, P; Oropesa-Ruiz, JM; Vargas-Gonzalez, L, 2016) |
| "Cognitive deficits are common in Parkinson's disease (PD) and many patients eventually develop dementia; however, its occurrence is unpredictable." | 1.43 | Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study. ( Amboni, M; Barone, P; Erro, R; Moccia, M; Pellecchia, MT; Picillo, M; Santangelo, G; Savastano, R; Siano, P; Vallelunga, A; Vitale, C, 2016) |
| "Uric acid (UA) has been studied extensively as a valuable biomarker of Parkinson's disease (PD), but its relationship with non-motor symptoms (NMS) in de novo PD has been poorly investigated." | 1.42 | Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease. ( Amboni, M; Barone, P; Capo, G; Erro, R; Longo, K; Moccia, M; Orefice, G; Palladino, R; Pellecchia, MT; Picillo, M; Santangelo, G; Vitale, C, 2015) |
| "We recruited 52 newly diagnosed, drug-naïve PD patients, and performed serum UA dosage and [(123) I]FP-CIT-SPECT." | 1.42 | Uric acid relates to dopamine transporter availability in Parkinson's disease. ( Amboni, M; Barone, P; Erro, R; Longo, K; Moccia, M; Palladino, R; Pappatà, S; Pellecchia, MT; Picillo, M; Vitale, C, 2015) |
| "Uric acid (UA) is an endogenous antioxidant which is known to reduce oxidative stress and also chelate iron ion." | 1.40 | Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study. ( Kim, TH; Lee, JH, 2014) |
| "17) and daily levodopa dosage (OR 4." | 1.40 | Serum uric acid concentration is linked to wearing-off fluctuation in Japanese Parkinson's disease patients. ( Fukae, J; Hatano, T; Hattori, N; Ishikawa, K; Shimo, Y; Takanashi, M; Tsuboi, Y; Tsugawa, J; Yoritaka, A, 2014) |
| "Following the intraperitoneal administration of silymarin (with MRP1, 2, 4 and 5 inhibitory effects), naringenin (with MRP1, 2 and 4 stimulatory effects), sulfinpyrazone (with MRP1, 4 and 5 inhibitory and MRP2 stimulatory effects) and allopurinol (with MRP4 stimulatory effect in doses of 100 mg/kg, 100 mg/kg, 100 mg/kg and 60 mg/kg, respectively, for one week before and after the administration of MPTP in C57B/6 mice in acute dosing regimen the striatal concentrations of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid has been measured using high-performance liquid chromatography." | 1.39 | Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. ( Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013) |
| "Uric acid (UA) is a product of purine metabolism and is a natural antioxidant that can relieve the oxidative stress that occurs in PD." | 1.38 | Lower serum UA levels in Parkinson's disease patients in the Chinese population. ( Guo, JF; He, D; Lei, LF; Shen, L; Tan, LM; Tang, BS; Wang, CY; Wang, YQ; Yan, XX; Zhang, HN, 2012) |
| "Cognitive changes are common in Parkinson's disease (PD)." | 1.37 | Uric acid and cognition in Parkinson's disease: a follow-up study. ( Annanmaki, T; Hakkinen, P; Murros, K; Parviainen, T; Pohja, M, 2011) |
| "Therapeutic development in Parkinson's disease is hampered by the paucity of well-validated biomarkers that can assist with diagnosis and/or tracking the progression of the disease." | 1.36 | Biomarkers in Parkinson's disease: a funder's perspective. ( Chowdhury, S; Eberling, J; Frasier, M; Sherer, T, 2010) |
| "009) and daily levodopa dosage (R(p)=-0." | 1.35 | Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. ( Andreadou, E; Boufidou, F; Gournaras, F; Nikolaou, C; Rentzos, M; Tsoutsou, A; Vassilopoulos, D; Zissimopoulos, V; Zournas, C, 2009) |
| "Uric acid was significantly reduced while glutathione was significantly increased in PD patients." | 1.35 | Metabolomic profiling to develop blood biomarkers for Parkinson's disease. ( Bogdanov, M; Bressman, SS; Flint Beal, M; Matson, T; Matson, WR; Saunders-Pullman, R; Wang, L, 2008) |
| "Cognitive dysfunction is common in Parkinson's disease (PD)." | 1.35 | Uric acid associates with cognition in Parkinson's disease. ( Annanmaki, T; Hokkanen, L; Murros, K; Pessala-Driver, A, 2008) |
| "Eighty-four incident cases of Parkinson's disease were diagnosed through 2000, and each was randomly matched to two controls by year of birth, race, and time of blood collection." | 1.34 | Plasma urate and risk of Parkinson's disease. ( Ascherio, A; Chen, H; O'Reilly, E; Schwarzschild, MA; Weisskopf, MG, 2007) |
| "Neuronal death associated with Parkinson's disease is commonly believed to be caused by oxygen- and nitrogen-derived free radical species." | 1.32 | The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds. ( Coates, PW; Everse, J, 2004) |
| "Uric acid and DA levels were significantly lower in the substantia nigra of PD by 54% and 85%, respectively." | 1.29 | Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. ( Church, WH; Ward, VL, 1994) |
| "Of these men, 92 subsequently developed idiopathic Parkinson's disease (IPD)." | 1.29 | Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. ( Davis, JW; Grandinetti, A; Morens, DM; Ross, GW; Waslien, CI; White, LR, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (3.75) | 18.7374 |
| 1990's | 4 (2.50) | 18.2507 |
| 2000's | 25 (15.63) | 29.6817 |
| 2010's | 83 (51.88) | 24.3611 |
| 2020's | 42 (26.25) | 2.80 |
| Authors | Studies |
|---|---|
| Schwarzschild, MA | 26 |
| Ascherio, A | 18 |
| Casaceli, C | 1 |
| Curhan, GC | 2 |
| Fitzgerald, R | 1 |
| Kamp, C | 1 |
| Lungu, C | 1 |
| Macklin, EA | 10 |
| Marek, K | 3 |
| Mozaffarian, D | 1 |
| Oakes, D | 7 |
| Rudolph, A | 4 |
| Shoulson, I | 6 |
| Videnovic, A | 1 |
| Scott, B | 1 |
| Gauger, L | 3 |
| Aldred, J | 1 |
| Bixby, M | 1 |
| Ciccarello, J | 1 |
| Gunzler, SA | 1 |
| Henchcliffe, C | 2 |
| Brodsky, M | 1 |
| Keith, K | 1 |
| Hauser, RA | 1 |
| Goetz, C | 2 |
| LeDoux, MS | 1 |
| Hinson, V | 1 |
| Kumar, R | 1 |
| Espay, AJ | 2 |
| Jimenez-Shahed, J | 1 |
| Hunter, C | 1 |
| Christine, C | 1 |
| Daley, A | 1 |
| Leehey, M | 1 |
| de Marcaida, JA | 1 |
| Friedman, JH | 3 |
| Hung, A | 2 |
| Bwala, G | 2 |
| Litvan, I | 1 |
| Simon, DK | 1 |
| Simuni, T | 2 |
| Poon, C | 1 |
| Schiess, MC | 1 |
| Chou, K | 1 |
| Park, A | 1 |
| Bhatti, D | 1 |
| Peterson, C | 1 |
| Criswell, SR | 1 |
| Rosenthal, L | 1 |
| Durphy, J | 1 |
| Shill, HA | 1 |
| Mehta, SH | 1 |
| Ahmed, A | 2 |
| Deik, AF | 1 |
| Fang, JY | 1 |
| Stover, N | 1 |
| Zhang, L | 1 |
| Dewey, RB | 1 |
| Gerald, A | 1 |
| Boyd, JT | 1 |
| Houston, E | 1 |
| Suski, V | 1 |
| Mosovsky, S | 1 |
| Cloud, L | 1 |
| Shah, BB | 1 |
| Saint-Hilaire, M | 1 |
| James, R | 2 |
| Zauber, SE | 1 |
| Reich, S | 1 |
| Shprecher, D | 1 |
| Pahwa, R | 1 |
| Langhammer, A | 1 |
| LaFaver, K | 1 |
| LeWitt, PA | 3 |
| Kaminski, P | 1 |
| Goudreau, J | 1 |
| Russell, D | 2 |
| Houghton, DJ | 1 |
| Laroche, A | 1 |
| Thomas, K | 1 |
| McGraw, M | 1 |
| Mari, Z | 1 |
| Serrano, C | 1 |
| Blindauer, K | 1 |
| Rabin, M | 1 |
| Kurlan, R | 1 |
| Morgan, JC | 1 |
| Soileau, M | 1 |
| Ainslie, M | 2 |
| Bodis-Wollner, I | 1 |
| Schneider, RB | 1 |
| Waters, C | 1 |
| Ratel, AS | 1 |
| Beck, CA | 1 |
| Bolger, P | 1 |
| Callahan, KF | 1 |
| Crotty, GF | 3 |
| Klements, D | 1 |
| Kostrzebski, M | 1 |
| McMahon, GM | 1 |
| Pothier, L | 1 |
| Waikar, SS | 1 |
| Lang, A | 1 |
| Mestre, T | 1 |
| Yao, C | 1 |
| Niu, L | 1 |
| Fu, Y | 1 |
| Zhu, X | 2 |
| Yang, J | 1 |
| Zhao, P | 1 |
| Sun, X | 1 |
| Ma, Y | 1 |
| Li, S | 2 |
| Li, J | 2 |
| Frucht, SJ | 1 |
| Koto, R | 1 |
| Sato, I | 1 |
| Kuwabara, M | 1 |
| Seki, T | 1 |
| Kawakami, K | 1 |
| Ari, BC | 1 |
| Tur, EK | 1 |
| Domac, FM | 1 |
| Kenangil, GO | 1 |
| Dănău, A | 1 |
| Dumitrescu, L | 1 |
| Lefter, A | 1 |
| Popescu, BO | 1 |
| Ramos, GK | 1 |
| Goldfarb, DS | 1 |
| Pou, MA | 1 |
| Orfila, F | 1 |
| Pagonabarraga, J | 1 |
| Ferrer-Moret, S | 1 |
| Corominas, H | 1 |
| Diaz-Torne, C | 1 |
| Luo, S | 1 |
| Zou, H | 1 |
| Stebbins, GT | 1 |
| Chan, J | 1 |
| Goetz, CG | 2 |
| Basile, MS | 1 |
| Bramanti, P | 1 |
| Mazzon, E | 1 |
| Seifar, F | 1 |
| Dinasarapu, AR | 1 |
| Jinnah, HA | 2 |
| Aerqin, Q | 1 |
| Jia, SS | 1 |
| Shen, XN | 1 |
| Li, Q | 2 |
| Chen, KL | 1 |
| Ou, YN | 1 |
| Huang, YY | 1 |
| Dong, Q | 1 |
| Chen, SF | 1 |
| Yu, JT | 1 |
| Şanlı, BA | 1 |
| Whittaker, KJ | 1 |
| Motsi, GK | 1 |
| Shen, E | 1 |
| Julian, TH | 1 |
| Cooper-Knock, J | 1 |
| Fazlollahi, A | 1 |
| Zahmatyar, M | 1 |
| Alizadeh, H | 1 |
| Noori, M | 1 |
| Jafari, N | 1 |
| Nejadghaderi, SA | 1 |
| Sullman, MJM | 1 |
| Gharagozli, K | 1 |
| Kolahi, AA | 1 |
| Safiri, S | 1 |
| Rajan, S | 3 |
| Kaas, B | 3 |
| Kunitskaya, NA | 1 |
| Ariev, AL | 1 |
| Cen, K | 1 |
| Cui, Y | 1 |
| Feng, X | 1 |
| Hou, X | 1 |
| Grofik, M | 1 |
| Cibulka, M | 1 |
| Oleksakova, J | 1 |
| Sivak, S | 1 |
| Cierny, D | 1 |
| Tatarkova, Z | 1 |
| Grendar, M | 1 |
| Nosal, V | 1 |
| Ruzinak, R | 1 |
| Kurca, E | 1 |
| Kolisek, M | 1 |
| Soares, NM | 1 |
| Pereira, GM | 1 |
| Dutra, ACL | 1 |
| Artigas, NR | 1 |
| Krimberg, JS | 1 |
| Monticelli, BE | 1 |
| Schumacher-Schuh, AF | 1 |
| Almeida, RMM | 1 |
| Rieder, CRM | 1 |
| Zhou, C | 1 |
| Gu, M | 1 |
| Yin, L | 1 |
| Yin, W | 1 |
| Liu, J | 1 |
| Zhu, Y | 1 |
| Yin, K | 1 |
| Lei, C | 1 |
| Xu, Z | 1 |
| Yang, X | 1 |
| Constantin, IM | 1 |
| Voruz, P | 1 |
| Péron, JA | 1 |
| Ma, C | 1 |
| Yu, R | 1 |
| Wang, X | 2 |
| Guo, J | 1 |
| Xiao, E | 1 |
| Liu, P | 1 |
| Koros, C | 4 |
| Simitsi, AM | 4 |
| Papagiannakis, N | 4 |
| Bougea, A | 4 |
| Prentakis, A | 4 |
| Papadimitriou, D | 4 |
| Pachi, I | 4 |
| Beratis, I | 4 |
| Stanitsa, E | 1 |
| Angelopoulou, E | 4 |
| Antonelou, R | 4 |
| Bregianni, M | 1 |
| Lourentzos, K | 1 |
| Papageorgiou, SG | 4 |
| Bonakis, A | 1 |
| Trapali, XG | 4 |
| Stamelou, M | 4 |
| Stefanis, L | 4 |
| Matsumura, N | 1 |
| Aoyama, K | 1 |
| Oh, YS | 1 |
| Kim, JS | 1 |
| Yoo, SW | 1 |
| Hwang, EJ | 1 |
| Lyoo, CH | 1 |
| Lee, KS | 1 |
| Chamorro, A | 1 |
| Mir, P | 5 |
| Liu, H | 1 |
| Wei, X | 2 |
| Yang, W | 1 |
| Reynolds, GP | 1 |
| Baik, K | 2 |
| Chung, SJ | 3 |
| Yoo, HS | 3 |
| Lee, YH | 3 |
| Jung, JH | 2 |
| Sohn, YH | 4 |
| Lee, PH | 4 |
| Schirinzi, T | 1 |
| Di Lazzaro, G | 1 |
| Sancesario, GM | 1 |
| Summa, S | 1 |
| Petrucci, S | 1 |
| Colona, VL | 1 |
| Bernardini, S | 1 |
| Pierantozzi, M | 1 |
| Stefani, A | 1 |
| Mercuri, NB | 1 |
| Pisani, A | 1 |
| Bozi, M | 3 |
| Bakshi, R | 5 |
| Hung, AY | 1 |
| Hayes, MT | 1 |
| Hyman, BT | 1 |
| Wills, AM | 1 |
| Gomperts, SN | 1 |
| Growdon, JH | 1 |
| Scherzer, CR | 1 |
| Ye, BS | 1 |
| van Wamelen, DJ | 1 |
| Taddei, RN | 1 |
| Calvano, A | 1 |
| Titova, N | 1 |
| Leta, V | 1 |
| Shtuchniy, I | 1 |
| Jenner, P | 1 |
| Martinez-Martin, P | 1 |
| Katunina, E | 1 |
| Chaudhuri, KR | 1 |
| Lee, Y | 2 |
| Cha, J | 1 |
| Von Seggern, M | 1 |
| Szarowicz, C | 1 |
| Swanson, M | 1 |
| Cavotta, S | 1 |
| Pike, ST | 1 |
| Lamberts, JT | 1 |
| Hasimoglu, YG | 1 |
| Chen, X | 6 |
| Lee, JJ | 2 |
| Baik, JS | 1 |
| Venkatesan, D | 1 |
| Iyer, M | 1 |
| S, RW | 1 |
| G, L | 1 |
| Vellingiri, B | 1 |
| Coneys, R | 1 |
| Storm, CS | 1 |
| Kia, DA | 2 |
| Almramhi, M | 1 |
| Wood, NW | 2 |
| Shi, X | 1 |
| Zheng, J | 1 |
| Ma, J | 1 |
| Wang, Z | 1 |
| Sun, W | 2 |
| Li, M | 1 |
| Huang, S | 2 |
| Hu, S | 1 |
| Wen, M | 1 |
| Zhou, B | 1 |
| Chen, YH | 1 |
| Ma, ZL | 1 |
| Gou, Y | 1 |
| Zhang, CL | 1 |
| Yu, WF | 1 |
| Jiao, L | 1 |
| Huertas, I | 1 |
| Jesús, S | 4 |
| Lojo, JA | 1 |
| García-Gómez, FJ | 1 |
| Cáceres-Redondo, MT | 4 |
| Oropesa-Ruiz, JM | 2 |
| Carrillo, F | 4 |
| Vargas-Gonzalez, L | 2 |
| Martín Rodríguez, JF | 1 |
| Gómez-Garre, P | 4 |
| García-Solís, D | 1 |
| Hemmati-Dinarvand, M | 2 |
| Taher-Aghdam, AA | 1 |
| Mota, A | 1 |
| Zununi Vahed, S | 2 |
| Samadi, N | 2 |
| Huang, TT | 1 |
| Hao, DL | 1 |
| Wu, BN | 1 |
| Mao, LL | 1 |
| Zhang, J | 1 |
| Yu, Z | 1 |
| Zhang, S | 1 |
| Wang, D | 1 |
| Fan, M | 1 |
| Gao, F | 1 |
| Li, Z | 1 |
| Iwaki, H | 1 |
| Ando, R | 1 |
| Miyaue, N | 1 |
| Tada, S | 1 |
| Tsujii, T | 1 |
| Yabe, H | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Nomoto, M | 1 |
| Gao, X | 7 |
| Yue, H | 1 |
| Song, S | 1 |
| Li, B | 1 |
| Lin, X | 1 |
| Guo, E | 1 |
| Wang, B | 1 |
| Guan, E | 1 |
| Zhang, H | 1 |
| Wu, P | 1 |
| Park, YH | 1 |
| Lee, JM | 1 |
| Cortese, M | 1 |
| Riise, T | 1 |
| Engeland, A | 1 |
| Bjørnevik, K | 1 |
| Huang, X | 2 |
| Ng, SY | 1 |
| Chia, NS | 1 |
| Acharyya, S | 1 |
| Setiawan, F | 1 |
| Lu, ZH | 1 |
| Ng, E | 1 |
| Tay, KY | 1 |
| Au, WL | 1 |
| Tan, EK | 1 |
| Tan, LC | 1 |
| Hughes, KC | 1 |
| O'Reilly, EJ | 3 |
| Kim, IY | 1 |
| Wang, M | 1 |
| Weisskopf, MG | 3 |
| Zhong, LL | 1 |
| Song, YQ | 1 |
| Tian, XY | 1 |
| Cao, H | 1 |
| Ju, KJ | 1 |
| König, IR | 2 |
| Greco, FMD | 1 |
| Kobylecki, CJ | 1 |
| Nordestgaard, BG | 1 |
| Afzal, S | 1 |
| Noyce, AJ | 1 |
| White, J | 1 |
| Speed, D | 1 |
| Nicolas, A | 1 |
| Burgess, S | 1 |
| Lawlor, DA | 1 |
| Davey Smith, G | 1 |
| Singleton, A | 1 |
| Nalls, MA | 1 |
| Sofat, R | 1 |
| Tana, C | 1 |
| Ticinesi, A | 1 |
| Prati, B | 1 |
| Nouvenne, A | 1 |
| Meschi, T | 1 |
| Brown, EG | 1 |
| Goldman, SM | 1 |
| Tanner, CM | 3 |
| Niknam, M | 1 |
| Umeh, CC | 1 |
| Tainsh, RE | 1 |
| Feng, DD | 1 |
| Maguire, M | 1 |
| Zuo, F | 1 |
| Rahimian, M | 1 |
| Logan, R | 4 |
| Buys, ES | 1 |
| Zorlu, MM | 1 |
| Xia, N | 1 |
| Zhang, E | 1 |
| Sleeman, I | 1 |
| Lawson, RA | 1 |
| Yarnall, AJ | 1 |
| Duncan, GW | 1 |
| Johnston, F | 1 |
| Khoo, TK | 1 |
| Burn, DJ | 1 |
| Ouzren, N | 1 |
| Delcambre, S | 1 |
| Ghelfi, J | 1 |
| Seibler, P | 1 |
| Farrer, MJ | 1 |
| Aasly, JO | 2 |
| Trinh, J | 1 |
| Klein, C | 2 |
| Grünewald, A | 1 |
| Schernhammer, E | 1 |
| Qiu, J | 1 |
| Wermuth, L | 1 |
| Lassen, CF | 1 |
| Friis, S | 1 |
| Ritz, B | 1 |
| McFarland, NR | 1 |
| Burdett, T | 1 |
| Desjardins, CA | 1 |
| Frosch, MP | 1 |
| Uribe-San Martín, R | 1 |
| Venegas Francke, P | 1 |
| López Illanes, F | 1 |
| Jones Gazmuri, A | 1 |
| Salazar Rivera, J | 1 |
| Godoy Ferńndez, J | 1 |
| Santín Martínez, J | 1 |
| Juri, C | 1 |
| González-Aramburu, I | 2 |
| Sánchez-Juan, P | 2 |
| Gorostidi, A | 1 |
| Fernández-Juan, E | 2 |
| Sierra, M | 2 |
| Berciano, J | 2 |
| Ruiz-Martínez, J | 1 |
| Combarros, O | 2 |
| Infante, J | 2 |
| Tabunoki, H | 1 |
| Ono, H | 1 |
| Ode, H | 1 |
| Ishikawa, K | 2 |
| Kawana, N | 1 |
| Banno, Y | 1 |
| Shimada, T | 1 |
| Nakamura, Y | 2 |
| Yamamoto, K | 1 |
| Satoh, J | 1 |
| Bono, H | 1 |
| Beal, MF | 3 |
| Cudkowicz, ME | 1 |
| Hare, JM | 1 |
| Hooper, DC | 1 |
| Kieburtz, KD | 1 |
| Tennis, MK | 1 |
| Gartner, M | 1 |
| Lenehan, R | 1 |
| Encarnacion, E | 1 |
| Castillo, R | 1 |
| Togasaki, D | 1 |
| Barles, G | 1 |
| Niles, L | 1 |
| Carter, JH | 1 |
| Murray, M | 1 |
| Jaglin, J | 1 |
| Russell, DS | 1 |
| Cotto, C | 1 |
| Goudreau, JL | 1 |
| Parashos, SA | 1 |
| Ede, P | 1 |
| Saint-Hilaire, MH | 1 |
| Thomas, CA | 1 |
| Stacy, MA | 1 |
| Johnson, J | 1 |
| Antonelle de Marcaida, J | 1 |
| Thurlow, S | 1 |
| Isaacson, SH | 1 |
| Carvajal, L | 1 |
| Rao, J | 1 |
| Cook, M | 1 |
| Hope-Porche, C | 1 |
| McClurg, L | 1 |
| Grasso, DL | 1 |
| Orme, C | 1 |
| Ross, T | 1 |
| Brocht, AF | 1 |
| Constantinescu, R | 4 |
| Sharma, S | 1 |
| Venuto, C | 1 |
| Weber, J | 1 |
| Eaton, K | 1 |
| Plangár, I | 1 |
| Zádori, D | 1 |
| Szalárdy, L | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 1 |
| Sánchez-Quintana, C | 1 |
| Kachroo, A | 2 |
| Moccia, M | 6 |
| Picillo, M | 5 |
| Erro, R | 5 |
| Vitale, C | 6 |
| Longo, K | 4 |
| Amboni, M | 5 |
| Santangelo, G | 4 |
| Spina, E | 3 |
| De Rosa, A | 1 |
| De Michele, G | 1 |
| Santoro, L | 1 |
| Barone, P | 6 |
| Pellecchia, MT | 6 |
| Coaker, H | 1 |
| Fukae, J | 1 |
| Hatano, T | 1 |
| Yoritaka, A | 1 |
| Takanashi, M | 1 |
| Shimo, Y | 1 |
| Tsugawa, J | 1 |
| Tsuboi, Y | 1 |
| Hattori, N | 1 |
| Palladino, R | 2 |
| Capo, G | 1 |
| Orefice, G | 2 |
| Sun, CL | 1 |
| Su, CH | 1 |
| Wu, JJ | 1 |
| Simon, KC | 1 |
| Eberly, S | 4 |
| Fahn, S | 3 |
| Pappatà, S | 1 |
| Kim, TH | 1 |
| Lee, JH | 1 |
| Chen, J | 1 |
| Yao, J | 1 |
| Wu, Y | 1 |
| Chen, Y | 1 |
| Mao, C | 1 |
| Liu, C | 1 |
| Qin, XL | 1 |
| Zhang, QS | 1 |
| Sun, L | 1 |
| Hao, MW | 1 |
| Hu, ZT | 1 |
| Scheperjans, F | 1 |
| Pekkonen, E | 1 |
| Kaakkola, S | 1 |
| Auvinen, P | 1 |
| Pakpoor, J | 1 |
| Seminog, OO | 1 |
| Ramagopalan, SV | 1 |
| Goldacre, MJ | 1 |
| Lolekha, P | 1 |
| Wongwan, P | 1 |
| Kulkantrakorn, K | 1 |
| Nazeri, A | 1 |
| Roostaei, T | 1 |
| Sadaghiani, S | 1 |
| Chakravarty, MM | 1 |
| Lang, AE | 3 |
| Voineskos, AN | 1 |
| Huertas-Fernández, I | 1 |
| Carballo, M | 2 |
| Prestipino, E | 1 |
| Sampat, R | 1 |
| Young, S | 1 |
| Rosen, A | 1 |
| Bernhard, D | 1 |
| Millington, D | 1 |
| Factor, S | 1 |
| Vieru, E | 1 |
| Köksal, A | 1 |
| Mutluay, B | 1 |
| Dirican, AC | 1 |
| Altunkaynak, Y | 1 |
| Baybas, S | 1 |
| Bhattacharyya, S | 1 |
| Pagano, G | 1 |
| Ferrara, N | 1 |
| Brooks, DJ | 1 |
| Pavese, N | 1 |
| Savastano, R | 1 |
| Siano, P | 1 |
| Vallelunga, A | 1 |
| Wang, L | 4 |
| Hu, W | 1 |
| Wang, J | 1 |
| Fang, F | 1 |
| Cheng, G | 1 |
| Jiang, Y | 1 |
| Xiao, H | 1 |
| Wan, Q | 1 |
| Paganoni, S | 1 |
| Sakuta, H | 1 |
| Suzuki, K | 1 |
| Miyamoto, T | 1 |
| Miyamoto, M | 1 |
| Numao, A | 1 |
| Fujita, H | 1 |
| Watanabe, Y | 1 |
| Hirata, K | 1 |
| Delamarre, A | 1 |
| Meissner, WG | 1 |
| Ou, R | 1 |
| Cao, B | 1 |
| Wei, Q | 1 |
| Hou, Y | 1 |
| Xu, Y | 2 |
| Song, W | 1 |
| Zhao, B | 1 |
| Shang, H | 1 |
| Schiess, M | 1 |
| Oh, I | 1 |
| Iwasaki, Y | 2 |
| Kano, O | 1 |
| Ikeda, K | 2 |
| Schlesinger, I | 2 |
| Schlesinger, N | 2 |
| De Vera, M | 1 |
| Rahman, MM | 1 |
| Rankin, J | 1 |
| Kopec, J | 1 |
| Choi, H | 1 |
| Chen, H | 4 |
| Mosley, TH | 1 |
| Alonso, A | 2 |
| Andreadou, E | 1 |
| Nikolaou, C | 1 |
| Gournaras, F | 1 |
| Rentzos, M | 1 |
| Boufidou, F | 1 |
| Tsoutsou, A | 1 |
| Zournas, C | 1 |
| Zissimopoulos, V | 1 |
| Vassilopoulos, D | 1 |
| Xu, K | 1 |
| Watts, A | 2 |
| Matson, WR | 3 |
| Marras, C | 1 |
| Kieburtz, K | 2 |
| Bogdanov, MB | 1 |
| Schwid, SR | 2 |
| Tennis, M | 1 |
| Johansen, KK | 1 |
| White, LR | 2 |
| Bogdanov, M | 2 |
| Wang, XJ | 1 |
| Luo, WF | 2 |
| Wang, LJ | 1 |
| Mao, CJ | 1 |
| Liu, CF | 1 |
| Perry, G | 1 |
| Moreira, PI | 1 |
| Siedlak, SL | 1 |
| Nunomura, A | 1 |
| Smith, MA | 1 |
| Winquist, A | 1 |
| Steenland, K | 1 |
| Shankar, A | 1 |
| Huang, YX | 1 |
| Sovell, KA | 1 |
| Facheris, MF | 1 |
| Hicks, AA | 1 |
| Minelli, C | 1 |
| Hagenah, JM | 1 |
| Kostic, V | 1 |
| Campbell, S | 1 |
| Hayward, C | 1 |
| Volpato, CB | 1 |
| Pattaro, C | 1 |
| Vitart, V | 1 |
| Wright, A | 1 |
| Campbell, H | 1 |
| Pramstaller, PP | 1 |
| Spiegelman, D | 1 |
| Morelli, M | 1 |
| Carta, AR | 1 |
| Nyhlén, J | 1 |
| Zetterberg, H | 3 |
| Cipriani, S | 1 |
| Frasier, M | 1 |
| Chowdhury, S | 1 |
| Eberling, J | 1 |
| Sherer, T | 1 |
| Kiyozuka, T | 1 |
| Aoyagi, J | 1 |
| Hirayama, T | 1 |
| Nagata, R | 1 |
| Ito, H | 1 |
| Iwamoto, K | 1 |
| Murata, K | 1 |
| Yoshii, Y | 1 |
| Kawabe, K | 1 |
| Annanmaki, T | 3 |
| Pohja, M | 1 |
| Parviainen, T | 1 |
| Hakkinen, P | 1 |
| Murros, K | 3 |
| Jennings, D | 1 |
| Seibyl, J | 2 |
| Jain, S | 1 |
| Ton, TG | 1 |
| Boudreau, RM | 1 |
| Yang, M | 1 |
| Thacker, EL | 1 |
| Studenski, S | 1 |
| Longstreth, WT | 1 |
| Strotmeyer, ES | 1 |
| Newman, AB | 1 |
| Zhang, HN | 1 |
| Guo, JF | 1 |
| He, D | 1 |
| Lei, LF | 1 |
| Wang, YQ | 1 |
| Wang, CY | 1 |
| Tan, LM | 1 |
| Yan, XX | 1 |
| Shen, L | 1 |
| Tang, BS | 1 |
| Sun, CC | 1 |
| Luo, FF | 1 |
| Wei, L | 1 |
| Lei, M | 1 |
| Li, GF | 1 |
| Liu, ZL | 1 |
| LE, WD | 1 |
| Xu, PY | 1 |
| Pérez, I | 1 |
| Wu, G | 1 |
| Andreasson, U | 1 |
| Holmberg, B | 1 |
| Pan, M | 1 |
| Gao, H | 1 |
| Long, L | 1 |
| Liu, M | 1 |
| Zou, J | 1 |
| Wu, A | 1 |
| Tang, B | 1 |
| Wang, Q | 1 |
| Shen, C | 1 |
| Guo, Y | 1 |
| Luo, W | 1 |
| Lin, C | 1 |
| Ding, M | 1 |
| Fitzmaurice, PS | 1 |
| Ang, L | 1 |
| Guttman, M | 1 |
| Rajput, AH | 1 |
| Furukawa, Y | 1 |
| Kish, SJ | 1 |
| Anderson, RF | 1 |
| Harris, TA | 1 |
| Everse, J | 1 |
| Coates, PW | 1 |
| de Lau, LM | 1 |
| Koudstaal, PJ | 1 |
| Hofman, A | 1 |
| Breteler, MM | 1 |
| Muuronen, A | 1 |
| O'Reilly, E | 1 |
| Matson, T | 1 |
| Saunders-Pullman, R | 1 |
| Bressman, SS | 1 |
| Flint Beal, M | 1 |
| Wise, BL | 1 |
| Neogi, T | 1 |
| Zhang, Y | 1 |
| Pessala-Driver, A | 1 |
| Hokkanen, L | 1 |
| Choi, HK | 1 |
| Curhan, G | 1 |
| Hyson, C | 1 |
| Gorbold, E | 1 |
| Forrest, M | 1 |
| Ondrasik, J | 1 |
| Bierer, DW | 1 |
| Quebbemann, AJ | 1 |
| Tohgi, H | 1 |
| Abe, T | 1 |
| Takahashi, S | 1 |
| Kikuchi, T | 1 |
| Church, WH | 1 |
| Ward, VL | 1 |
| Davis, JW | 1 |
| Grandinetti, A | 1 |
| Waslien, CI | 1 |
| Ross, GW | 1 |
| Morens, DM | 1 |
| Serra, PA | 1 |
| Esposito, G | 1 |
| Enrico, P | 1 |
| Mura, MA | 1 |
| Migheli, R | 1 |
| Delogu, MR | 1 |
| Miele, M | 1 |
| Desole, MS | 1 |
| Grella, G | 1 |
| Miele, E | 1 |
| Loeffler, DA | 1 |
| Camp, DM | 1 |
| Juneau, PL | 1 |
| Harel, E | 1 |
| Kawachi, M | 1 |
| Kono, N | 1 |
| Kiyokawa, H | 1 |
| Mineo, I | 1 |
| Nakajima, H | 1 |
| Shimizu, T | 1 |
| Yorifuji, S | 1 |
| Kuwajima, M | 1 |
| Tarui, S | 1 |
| Barbeau, A | 1 |
| Mars, H | 1 |
| Botez, MI | 1 |
| Joubert, M | 1 |
| Honda, H | 1 |
| Gindin, RA | 1 |
| Jonas, S | 1 |
| al-Hujaj, M | 1 |
| Schönthal, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease[NCT02642393] | Phase 3 | 298 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease[NCT00833690] | Phase 2 | 75 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effects of Food on the Pharmacokinetics of Urate After a Single Dose of Inosine in Healthy Male Subjects[NCT02614469] | Phase 1 | 18 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)[NCT03168711] | Phase 2 | 48 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)[NCT02288091] | Phase 1 | 32 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Neural Correlates of Multisensory Stimulation in Healthy Older Adults[NCT06174740] | 50 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | |||
| Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD[NCT00817453] | 150 participants (Anticipated) | Observational | 2009-01-31 | Terminated (stopped due to All subjects transferred to long term study NCT00817726 RBD Longitudinal) | |||
| A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease[NCT00040404] | Phase 2/Phase 3 | 806 participants (Actual) | Interventional | 2002-03-31 | Terminated (stopped due to Unlikely to provide evidence of significant effect) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Rate of change in points on the Montreal Cognitive Assessment (MoCA) scale (for cognition; over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group. The MoCA assesses attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Points are awarded for the correct completion of MoCA tasks. Scores for each task are summed for a total score (range 0-30). Higher scores indicate greater cognitive capacity. (NCT02642393)
Timeframe: two years
| Intervention | score per year (Mean) |
|---|---|
| Inosine | 0.186 |
| Placebo | 0.226 |
Rate of change in Parkinson's Disease Questionnaire - 39 item version (PDQ-39) scale points (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group. The PDQ-39 asks 39 questions organized over eight domains (scales): mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items), and bodily discomfort (3 items). Each item has five possible ordinal responses, from never to always, depending on frequency of the symptom over the preceding month. The eight scales' scores are generated by Likert's method of summated ratings and then transformed to a single figure that ranges from 0 to 100. Higher scores are associated with more symptoms. (NCT02642393)
Timeframe: two years
| Intervention | score per year (Mean) |
|---|---|
| Inosine | 0.686 |
| Placebo | 0.756 |
Rate of change in Quality of Life in Neurological Disorders (Neuro-QOL) depression module scale points (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group. Neuro-QOL is a set of patient-reported outcome (PRO) measures that assess health-related quality of life (HRQoL) of people with neurological disorders. Higher raw scores are associated with more of the concept being measured. The depression module score ranges from 8 to 40. (NCT02642393)
Timeframe: two years
| Intervention | score per year (Mean) |
|---|---|
| Inosine | -0.023 |
| Placebo | 0.083 |
"Rate of change in percentage points on the Schwab and England scale for functional disability (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group. The Schwab and England scale is a Site Investigator and subject assessment of the subject's level of independence. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living. Printed scores with associated descriptors range from 0% to 100% in increments of 5%, with higher percentages associated with more independence. A score of 0% implies vegetative functions such as swallowing, bladder and bowel functions are not functioning; bedridden. A score of 100% implies subject has full ability and is completely independent; essentially normal." (NCT02642393)
Timeframe: two years
| Intervention | score per year (Mean) |
|---|---|
| Inosine | -0.833 |
| Placebo | -0.880 |
Safety of oral inosine titrated to elevate trough serum urate to 7.1 - 8.0 mg/dL will be evaluated by comparing active vs. placebo treatment with respect to the percentage of subjects experiencing individual types of AE, as classified by Medical Dictionary for Regulatory Activities (MedDRA) preferred term and system organ class. (NCT02642393)
Timeframe: two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Inosine | 129 |
| Placebo | 137 |
The primary outcome of the trial is rate of change in the Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS) I-III total score over 24 months estimated from a shared-baseline, random-slopes mixed model, censoring follow-up of subjects after initiation of dopaminergic therapy. Parts I-III of the MDS-UPDRS include ratings of non-motor experiences of daily living, motor experiences of daily living, and a motor examination. The MDS-UPDRS is assessed on a 5-point Likert scale ranging from 0 to 4 where higher scores imply worse symptoms. Parts I-III contain 59 total questions (13 in Part I, 13 in Part II, and 33 in Part III). Total scores for Parts I-III are calculated as simple sums of component items with mean imputation by Part if no more than 1, 2, or 7 items are missing for Parts I through III, respectively. Total scores may range from 0 to 236, with 0 meaning no symptoms and 236 meaning worse symptoms. (NCT02642393)
Timeframe: two years
| Intervention | score per year (Mean) |
|---|---|
| Inosine | 11.116 |
| Placebo | 9.860 |
Safety also will be evaluated by comparing active vs. placebo treatment with respect to overall adverse event (AE) and serious AE (SAE) rate. (NCT02642393)
Timeframe: two years
| Intervention | Events per 100 patient-years (Number) |
|---|---|
| Inosine | 354.05 |
| Placebo | 327.73 |
Rate of change in Quality of Life in Neurological Disorders (Neuro-QOL) scale points (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group. Neuro-QOL is a set of patient-reported outcome (PRO) measures that assess health-related quality of life (HRQoL) of people with neurological disorders. It comprises 17 domains of HRQL covering physical, psychological and social health. Domains tested include anxiety, cognitive function, communication, depression, emotional and behavioral dyscontrol, fatigue, lower extremity function- mobility, positive affect and well- being, stigma, upper extremity function- fine motor and ADL, sleep disturbance, satisfaction with social roles and activities, and ability to participate in social roles and activities. Higher raw scores are associated with more of the concept being measured. All scales range from 8 to 40 except for Positive Affect and Well-Being which ranges from 9 to 45. (NCT02642393)
Timeframe: two years
| Intervention | score per year (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety | Cognitive Function | Communication | Emotional and Behavioral Dyscontrol | Fatigue | Lower Extremity Function | Positive Affect and Well-Being | Stigma | Upper Extremity Function | Sleep Disturbance | Satisfaction with Social Roles and Activities | Participation in Social Roles and Activities | |
| Inosine | -0.397 | 0.014 | 0.055 | -0.229 | -0.049 | -0.092 | -0.240 | -0.060 | -0.026 | 0.091 | -0.387 | -0.382 |
| Placebo | -0.473 | -0.282 | -0.201 | -0.324 | -0.040 | -0.261 | 0.094 | 0.021 | -0.238 | 0.020 | -0.381 | -0.130 |
The percentage of participants with disability warranting the initiation of dopaminergic therapy in each treatment group at time from baseline visit (in 180 day increments). (NCT02642393)
Timeframe: two years
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| 0 Days | 180 Days | 360 Days | 540 Days | 720 Days | |
| Inosine | 0 | 30.81 | 59.01 | 72.21 | 84.57 |
| Placebo | 0 | 32.42 | 56.32 | 78.55 | 88.27 |
Tolerability of a treatment will be defined as a percentage of all subjects in a treatment group who are tolerant of the treatment at 12 weeks (short-term tolerability) and 24 months (long-term tolerability). A subject who is tolerant of treatment will be defined as one who remains on-study and on the assigned treatment without one or more dose reductions lasting more than 4 weeks cumulative due to AEs. A treatment will be declared tolerable if the percentage who are tolerant is significantly greater than 50% by one-tailed testing at p < 0.05. (NCT02642393)
Timeframe: three months; two years
| Intervention | percentage of subjects (Number) | ||
|---|---|---|---|
| 12 weeks | 12 months | 24 months | |
| Inosine | 93.2 | 76.1 | 50.3 |
| Placebo | 98.7 | 91.3 | 70.8 |
Symptomatic effects will be estimated by changes in motor and other features (e.g., as assessed by short-term change in Movement Disorders Society Unified PD Rating Scale [MDS-UPDRS] I-III total score) during the first 3 months of wash-in at the start of period 1 and during the 3-month wash-out of period 2. The MDS-UPDRS includes ratings of non-motor experiences of daily living, motor experiences of daily living, and a motor examination. The MDS-UPDRS is assessed on a 5-point Likert scale ranging from 0 to 4 where higher scores imply worse features. Parts I-III contain 59 total questions (13 in Part I, 13 in Part II, and 33 in Part III). Total scores are calculated as simple sums of component items with mean imputation by Part if no more than 1, 2, or 7 items are missing for Parts I through III, respectively. Total scores may range from 0 to 236, with 0 meaning no symptoms and 236 meaning worse symptoms. (NCT02642393)
Timeframe: three months (after both initiation and discontinuation of study drug)
| Intervention | score per period (Mean) | |
|---|---|---|
| Period 1: BL to V03 | Period 2: V10 to SV | |
| Inosine | -1.509 | -2.729 |
| Placebo | -1.301 | -0.328 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Safety Visit (SV) from Baseline (i.e., between -45 days and +760 days [+1 month after ESD Visit])
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 0.1 |
| [B:]Mild | 0.35 |
| [C.]Moderate | -0.11 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 01 from Baseline (i.e., between -45 days and +2 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 0.15 |
| [B:]Mild | 2.1 |
| [C.]Moderate | 2.44 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 02 from Baseline (i.e., between -45 days and +4 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 0.09 |
| [B:]Mild | 2.24 |
| [C.]Moderate | 3.41 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 03 from Baseline (i.e., between -45 days and +6 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 0.22 |
| [B:]Mild | 2.35 |
| [C.]Moderate | 3.02 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 04 from Baseline (i.e., between -45 days and +9 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | -0.02 |
| [B:]Mild | 2.47 |
| [C.]Moderate | 3.13 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 05 from Baseline (i.e., between -45 days and +12 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 0.1 |
| [B:]Mild | 1.51 |
| [C.]Moderate | 2.42 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 06 from Baseline (i.e., between -45 days and +6 months)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 0.21 |
| [B:]Mild | 2.55 |
| [C.]Moderate | 3.78 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 07 from Baseline (i.e., between -45 days and +9 months)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 0.14 |
| [B:]Mild | 2.43 |
| [C.]Moderate | 3.56 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 08 from Baseline (i.e., between -45 days and +12 months)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 0.2 |
| [B:]Mild | 2.46 |
| [C.]Moderate | 2.96 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 09 from Baseline (i.e., between -45 days and +15 months)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 0 |
| [B:]Mild | 2.9 |
| [C.]Moderate | 3.19 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 10 from Baseline (i.e., between -45 days and +18 months)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | -0.07 |
| [B:]Mild | 2.49 |
| [C.]Moderate | 3.26 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 11 from Baseline (i.e., between -45 days and +21 months)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | -0.07 |
| [B:]Mild | 2.53 |
| [C.]Moderate | 3.11 |
Change from an Average of Baseline and Screening Visits (NCT00833690)
Timeframe: Visit 12 from Baseline (i.e., between -45 days and +24 months)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | -0.29 |
| [B:]Mild | 2.22 |
| [C.]Moderate | 2.93 |
Change from Last Visit on Study Drug (NCT00833690)
Timeframe: Safety Visit (SV) from End of Study Drug Visit (ESD); i.e., between +263 and +760 days)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 0.12 |
| [B:]Mild | -1.8 |
| [C.]Moderate | -3.2 |
Urate concentration in cerebrospinal fluid (CSF) (NCT00833690)
Timeframe: 12 weeks
| Intervention | mcg/dL (Mean) |
|---|---|
| [A:]Placebo | 427 |
| [B:]Mild | 544 |
| [C.]Moderate | 594 |
(NCT00833690)
Timeframe: 12 weeks
| Intervention | mcg/dL (Mean) |
|---|---|
| [A:]Placebo | 285 |
| [B:]Mild | 517 |
| [C.]Moderate | 575 |
(NCT00833690)
Timeframe: 12 weeks
| Intervention | mcg/dL (Mean) |
|---|---|
| [A:]Placebo | 546 |
| [B:]Mild | 586 |
| [C.]Moderate | 619 |
Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12). (NCT00833690)
Timeframe: 12 weeks
| Intervention | percentage of baseline serum urate (Mean) |
|---|---|
| [A:]Placebo | 9.6 |
| [B:]Mild | 13.1 |
| [C.]Moderate | 13.4 |
Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12). (NCT00833690)
Timeframe: 12 weeks
| Intervention | percentage of baseline serum urate (Mean) |
|---|---|
| [A:]Placebo | 6.7 |
| [B:]Mild | 13.5 |
| [C.]Moderate | 13.3 |
Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12). (NCT00833690)
Timeframe: 12 weeks
| Intervention | percentage of baseline serum urate (Mean) |
|---|---|
| [A:]Placebo | 12.0 |
| [B:]Mild | 12.4 |
| [C.]Moderate | 13.4 |
Defined as absence of serious adverse experiences (SAEs) that warranted terminating an inosine treatment arm or the trial, as determined by the Data and Safety Monitoring Committee. (NCT00833690)
Timeframe: 24 months
| Intervention | Events (Number) |
|---|---|
| [A:]Placebo | 11 |
| [B:]Mild | 2 |
| [C.]Moderate | 4 |
From blood sample drawn a month after stopping study drug (NCT00833690)
Timeframe: Safety Visit (SV); 30 +/- 3 days following ESD or Month 24 Visit
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.74 |
| [B:]Mild | 4.69 |
| [C.]Moderate | 4.38 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: End of Study Drug Visit (ESD) (Month 9-24; 263-727 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.66 |
| [B:]Mild | 6.48 |
| [C.]Moderate | 7.55 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 01 (Week 2; 14 +/- 3 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.8 |
| [B:]Mild | 6.44 |
| [C.]Moderate | 6.93 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 02 (Week 4; 28 +/- 3 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.73 |
| [B:]Mild | 6.58 |
| [C.]Moderate | 7.9 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 03 (Week 6; 42 +/- 3 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.85 |
| [B:]Mild | 6.69 |
| [C.]Moderate | 7.51 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 04 (Week 9; 63 +/- 5 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.62 |
| [B:]Mild | 6.81 |
| [C.]Moderate | 7.62 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 06 (Month 6; 180 +/- 7 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.85 |
| [B:]Mild | 6.94 |
| [C.]Moderate | 8.27 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 07 (Month 9; 270 +/- 7 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.77 |
| [B:]Mild | 6.77 |
| [C.]Moderate | 8.06 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 08 (Month 12; 360 +/- 7 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.79 |
| [B:]Mild | 6.87 |
| [C.]Moderate | 7.41 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 09 (Month 15; 450 +/- 7 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.62 |
| [B:]Mild | 7.26 |
| [C.]Moderate | 7.64 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 10 (Month 18; 540 +/- 7 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.58 |
| [B:]Mild | 7 |
| [C.]Moderate | 7.64 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 11 (Month 21; 630 +/- 7 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.6 |
| [B:]Mild | 7.12 |
| [C.]Moderate | 7.56 |
From blood sample drawn after taking study drug that day (NCT00833690)
Timeframe: Visit 12 (Month 24; 720 +/- 7 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.41 |
| [B:]Mild | 6.84 |
| [C.]Moderate | 7.19 |
From blood sample drawn before taking study drug that day (NCT00833690)
Timeframe: Visit 05 (Week 12; 84 +/- 7 days after Baseline Visit)
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.74 |
| [B:]Mild | 5.85 |
| [C.]Moderate | 6.91 |
From blood sample drawn prior to enrollment (NCT00833690)
Timeframe: Baseline Visit
| Intervention | mg/dL (Mean) |
|---|---|
| [A:]Placebo | 4.54 |
| [B:]Mild | 4.32 |
| [C.]Moderate | 4.62 |
Defined as the extent to which assigned treatment could continue without prolonged dose reduction (>48 consecutive days or >73 cumulative days, which is 10% of total 2-year follow-up) due to adverse experiences (AEs), and was assessed after 6 and 24 months on study drug. Units of measure are percentage points (i.e., % of participants in the group). (NCT00833690)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| [A:]Placebo | 96 |
| [B:]Mild | 96 |
| [C.]Moderate | 100 |
Defined as the extent to which assigned treatment could continue without prolonged dose reduction (>48 consecutive days or >73 cumulative days, which is 10% of total 2-year follow-up) due to AEs, and was assessed after 6 and 24 months on study drug. Units of measure are percentage points (i.e., % of participants in the group). (NCT00833690)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| [A:]Placebo | 86 |
| [B:]Mild | 92 |
| [C.]Moderate | 96 |
From blood sample drawn prior to enrollment (NCT00833690)
Timeframe: Screening Visits, up to 45 days prior to Baseline Visit. Specifically, Screening Visit 1 occurred between day -45 and -4; Screening Visit 2 occurred between day -43 and -2.
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Screening Visit 1 | Screening Visit 2 | |
| [A:]Placebo | 4.63 | 4.78 |
| [B:]Mild | 4.28 | 4.4 |
| [C.]Moderate | 4.39 | 4.48 |
(NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | mg*hr/dL (Mean) |
|---|---|
| Inosine Fed | 2040 |
| Inosine Fasted | 2031 |
(NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | mg*hr/dL (Mean) |
|---|---|
| Inosine Fed | 267 |
| Inosine Fasted | 268 |
Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post-dose
| Intervention | mg*hr/dL (Mean) |
|---|---|
| Inosine Fed | 80.4 |
| Inosine Fasted | 83.0 |
Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero. (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | mg*hr/dL (Mean) |
|---|---|
| Inosine Fed | 36.1 |
| Inosine Fasted | 39.3 |
Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero. (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | mg/dL (Mean) |
|---|---|
| Inosine Fed | 1.73 |
| Inosine Fasted | 1.65 |
Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | hr (Mean) |
|---|---|
| Inosine Fed | 44.3 |
| Inosine Fasted | 44.7 |
Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 h pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post-dose
| Intervention | hr (Median) |
|---|---|
| Inosine Fed | 3.0 |
| Inosine Fasted | 3.0 |
(NCT02614469)
Timeframe: -12 to 0 hrs pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hrs post-dose
| Intervention | mg/dL (Mean) |
|---|---|
| Inosine Fed | 6.6 |
| Inosine Fasted | 6.4 |
Number of participants with clinically significant findings in vital signs by investigator after study drug administration. (NCT02614469)
Timeframe: Up to 10 days after first study drug administration at Day 1 of Period 1
| Intervention | participants (Number) |
|---|---|
| Inosine Fed | 0 |
| Inosine Fasted | 0 |
Number of participants with adverse events after study drug administration (NCT02614469)
Timeframe: Up to 10 days after first study drug administration at Day 1 of Period 1
| Intervention | participants (Number) |
|---|---|
| Inosine Fed | 0 |
| Inosine Fasted | 0 |
(NCT02614469)
Timeframe: -12 to 0 pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | hr (Mean) |
|---|---|
| Inosine Fed | 242 |
| Inosine Fasted | 241 |
(NCT02614469)
Timeframe: -12 to 0 hr pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | hr (Median) |
|---|---|
| Inosine Fed | 3.0 |
| Inosine Fasted | 3.0 |
Safety will be assessed by the occurrence of adverse events such as kidney stones and gout (expected adverse events) in all participants receiving at least 1 dose of study drug (NCT03168711)
Timeframe: Baseline to Week 24
| Intervention | participants (Number) |
|---|---|
| Inosine | 11 |
| Placebo | 7 |
Tolerance of study drug will be defined as the number of participants who able to complete the 20-week study without permanently discontinuing study drug or suspending study drug for greater than 28 days (NCT03168711)
Timeframe: Baseline to Week 20
| Intervention | Participants (Count of Participants) |
|---|---|
| Inosine | 12 |
| Placebo | 7 |
Safety will be assessed by the occurrence of adverse events. (NCT02288091)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Open-label | 22 |
Tolerability will be defined as the ability of subjects to complete the entire 12-week study on study drug. (NCT02288091)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Open-label | 24 |
Blood samples will be obtained at baseline and after 12 weeks of treatment to measure biomarkers of oxidative stress and damage such as ferric reducing antioxidant power (FRAP). (NCT02288091)
Timeframe: 12 weeks
| Intervention | µM (Mean) | |
|---|---|---|
| Ferric Reducing Antioxidant Power (Baseline) | Ferric Reducing Antioxidant Power (Week 12) | |
| Open-label | 765.7 | 1188.3 |
Blood samples will be obtained at baseline and after 12 weeks of treatment to measure biomarkers of oxidative stress and damage such as glutathione (GSH). (NCT02288091)
Timeframe: 12 weeks
| Intervention | ƥM (Mean) | |
|---|---|---|
| Glutathione at Baseline | Glutathione at Week 12 | |
| Open-label | 94.0 | 84.5 |
Magnetic resonance spectroscopy (MRS) will be performed to measure the levels of glutathione in the motor cortex; levels of glutathione at Week 12 (post-treatment) will be compared to pre-treatment levels. (NCT02288091)
Timeframe: 12 weeks
| Intervention | mM (Mean) | |
|---|---|---|
| Motor Cortex Precentral Gyri (Baseline) | Motor Cortex Precentral Gyri (Week 12) | |
| Open-label | 0.424 | 0.392 |
25 reviews available for uric acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Update on Uric Acid and the Kidney.
Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Kidney; Male; Parkinson Disease; Renal Insuffi | 2022 |
Inosine in Neurodegenerative Diseases: From the Bench to the Bedside.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Humans; Inosine; Multiple Sclerosis; | 2022 |
Uric Acid in Parkinson's Disease: What Is the Connection?
Topics: Antioxidants; Biomarkers; Humans; Oxidative Stress; Parkinson Disease; Uric Acid | 2022 |
Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis.
Topics: Antioxidants; Case-Control Studies; Female; Gout; Humans; Male; Parkinson Disease; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
[The role of hyperuricemia in the development of cognitive changes in the elderly.]
Topics: Aged; Alzheimer Disease; Cognition; Cognitive Dysfunction; Dementia; Dementia, Vascular; Humans; Hyp | 2022 |
Uric acid levels and their association with vascular dementia and Parkinson's disease dementia: a meta-analysis.
Topics: Alzheimer Disease; Dementia; Dementia, Vascular; Humans; Parkinson Disease; Reproducibility of Resul | 2023 |
Glutathione-Mediated Neuroprotective Effect of Purine Derivatives.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Brain; Caffeine; Cysteine; Excitatory Amino Ac | 2023 |
Purine molecules in Parkinson's disease: Analytical techniques and clinical implications.
Topics: Animals; Biomarkers; Brain; Humans; Mass Spectrometry; Metabolomics; Parkinson Disease; Photoelectro | 2020 |
Serum uric acid levels in patients with Parkinson's disease: A meta-analysis.
Topics: Humans; Parkinson Disease; Uric Acid | 2017 |
Targeting urate to reduce oxidative stress in Parkinson disease.
Topics: Animals; Antioxidants; Disease Progression; Humans; Neuroprotective Agents; Oxidative Stress; Parkin | 2017 |
The significance of uric acid in the diagnosis and treatment of Parkinson disease: An updated systemic review.
Topics: Age Factors; Biomarkers; Disease Progression; Humans; Hyperuricemia; Movement Disorders; Oxidative S | 2017 |
Uric Acid and Cognitive Function in Older Individuals.
Topics: Aged; Alzheimer Disease; Cognition; Cognitive Dysfunction; Dementia; Dementia, Vascular; Disease Pro | 2018 |
Linking Smoking, Coffee, Urate, and Parkinson's Disease - A Role for Gut Microbiota?
Topics: Animals; Coffee; Gastrointestinal Microbiome; Humans; Parkinson Disease; Risk Factors; Smoking; Uric | 2015 |
Prospective study of plasma urate and risk of Parkinson disease in men and women.
Topics: Adult; Aged; Case-Control Studies; Female; Humans; Logistic Models; Male; Middle Aged; Parkinson Dis | 2016 |
Urate as a Marker of Risk and Progression of Neurodegenerative Disease.
Topics: Animals; Biomarkers; Clinical Trials as Topic; Disease Progression; Humans; Neurodegenerative Diseas | 2017 |
Epidemiology, environmental risk factors and genetics of Parkinson's disease.
Topics: Age Distribution; Age of Onset; alpha-Synuclein; Caffeine; Causality; Gene-Environment Interaction; | 2017 |
Uric acid in Parkinson's disease.
Topics: Antioxidants; Humans; Parkinson Disease; Uric Acid | 2008 |
Gout, hyperuricemia, and Parkinson's disease: a protective effect?
Topics: Aged; Biomarkers; Clinical Trials as Topic; Comorbidity; Female; Gout; Humans; Hyperuricemia; Male; | 2010 |
Pathophysiological roles for purines: adenosine, caffeine and urate.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Caffeine; Dopamine; Humans; Neuroprotective Agents; Pa | 2010 |
Problems associated with fluid biomarkers for Parkinson's disease.
Topics: alpha-Synuclein; Amyloid beta-Peptides; Biomarkers; Homovanillic Acid; Humans; Hydroxyindoleacetic A | 2010 |
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.
Topics: Biomarkers; Gout; Humans; Oxidative Stress; Parkinson Disease; Prognosis; Risk Factors; Urate Oxidas | 2010 |
Urate as a marker of development and progression in Parkinson's disease.
Topics: Biomarkers; Disease Progression; Humans; Parkinson Disease; Risk; Uric Acid | 2011 |
Urate in Parkinson's disease: more than a biomarker?
Topics: Animals; Antioxidants; Biomarkers; Humans; Neuroprotective Agents; Oxidative Stress; Parkinson Disea | 2012 |
Serum urate and the risk of Parkinson's disease: results from a meta-analysis.
Topics: Aged; Databases, Factual; Disease Progression; Female; Humans; Male; Middle Aged; Odds Ratio; Parkin | 2013 |
10 trials available for uric acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
Topics: Aged; Biomarkers; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Double-Blind Met | 2021 |
One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Female; Humans; | 2017 |
Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease.
Topics: Animals; Blood Pressure; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Knockout; Middle | 2018 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Topics: Aged; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; Inosine; Male; Middle Aged | 2014 |
Mendelian randomization of serum urate and parkinson disease progression.
Topics: Biomarkers; Disease Progression; Follow-Up Studies; Glucose Transport Proteins, Facilitative; Humans | 2014 |
Age at onset and Parkinson disease phenotype.
Topics: Age of Onset; Aged; alpha-Synuclein; Amyloid beta-Peptides; Biomarkers; Caudate Nucleus; Databases, | 2016 |
Urate as a predictor of the rate of clinical decline in Parkinson disease.
Topics: Biomarkers; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2009 |
[Study on uric acid and the related factors associated with cognition in the patients with Parkinson's disease].
Topics: Aged; Cognition Disorders; Female; Humans; Male; Middle Aged; Parkinson Disease; Risk Factors; Uric | 2009 |
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.
Topics: Biomarkers; Cohort Studies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Hum | 2008 |
Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.
Topics: Age Factors; Alkaline Phosphatase; Amantadine; Blood Glucose; Blood Urea Nitrogen; Clinical Trials a | 1971 |
125 other studies available for uric acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Cognition, motor symptoms, and glycolipid metabolism in Parkinson's disease with depressive symptoms.
Topics: Cognition; Depression; Glycolipids; Humans; Mental Status and Dementia Tests; Parkinson Disease; Uri | 2022 |
Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease-Reply.
Topics: Disease Progression; Humans; Inosine; Parkinson Disease; Uric Acid | 2022 |
Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease.
Topics: Disease Progression; Humans; Inosine; Parkinson Disease; Uric Acid | 2022 |
Temporal trends in the prevalence and characteristics of hypouricaemia: a descriptive study of medical check-up and administrative claims data.
Topics: Child; Female; Humans; Hypertension; Male; Parkinson Disease; Prevalence; Purine-Pyrimidine Metaboli | 2022 |
Uric acid: The role in the pathophysiology and the prediction in the diagnosis of Parkinson's disease: A Turkish-based study.
Topics: Humans; Mental Status and Dementia Tests; Parkinson Disease; Prospective Studies; Severity of Illnes | 2022 |
Serum Uric Acid Levels in Parkinson's Disease: A Cross-Sectional Electronic Medical Record Database Study from a Tertiary Referral Centre in Romania.
Topics: Cross-Sectional Studies; Electronic Health Records; Humans; Parkinson Disease; Romania; Tertiary Car | 2022 |
Risk of Parkinson's disease in a gout Mediterranean population: A case-control study.
Topics: Adult; Aged; Case-Control Studies; Cohort Studies; Female; Gout; Humans; Male; Neuroprotective Agent | 2022 |
Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.
Topics: Bayes Theorem; Humans; Inosine; Levodopa; Parkinson Disease; Severity of Illness Index; Tremor; Uric | 2022 |
Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study.
Topics: Alzheimer Disease; Cross-Sectional Studies; Frontotemporal Dementia; Humans; Multiple System Atrophy | 2022 |
Unbiased metabolome screen links serum urate to risk of Alzheimer's disease.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Genome-Wide Association Study; Humans; Mendelian R | 2022 |
Oxidative stress parameters and their relation to motor subtype of Parkinson's disease and levodopa treatment status.
Topics: Antioxidants; Female; Glutathione; Humans; Levodopa; Oxidative Stress; Parkinson Disease; Uric Acid | 2023 |
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Parkinson Disease; Uric Acid | 2023 |
Low serum uric acid levels may be a potential biomarker of poor sleep quality in patients with Parkinson's disease.
Topics: Biomarkers; Humans; Parkinson Disease; Sleep Quality; Sleep Wake Disorders; Uric Acid | 2023 |
Moderating effects of uric acid and sex on cognition and psychiatric symptoms in asymmetric Parkinson's disease.
Topics: Cognition; Female; Functional Laterality; Humans; Male; Mental Disorders; Parkinson Disease; Uric Ac | 2023 |
Association of serum uric acid levels with bone mineral density and the presence of osteoporosis in Chinese patients with Parkinson's disease: a cross-sectional study.
Topics: Bone Density; Cross-Sectional Studies; East Asian People; Humans; Osteoporosis; Parkinson Disease; U | 2023 |
Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson's Disease: Longitudinal Data from the PPMI Study.
Topics: Anosmia; Biomarkers; Humans; Parkinson Disease; Prodromal Symptoms; REM Sleep Behavior Disorder; Uri | 2023 |
Gender difference in the effect of uric acid on striatal dopamine in early Parkinson's disease.
Topics: Aged; Aged, 80 and over; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Fem | 2020 |
Raising serum urate levels in Parkinson disease: A strategy only for women?
Topics: Disease Progression; Female; Humans; Male; Parkinson Disease; Sex Characteristics; Uric Acid | 2019 |
Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson's disease.
Topics: Aged; China; Farmers; Female; Humans; Male; Middle Aged; Occupational Diseases; Parkinson Disease; R | 2020 |
Sex-dependent association of urate on the patterns of striatal dopamine depletion in Parkinson's disease.
Topics: Aged; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Male; | 2020 |
Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features.
Topics: Adult; Age Factors; Age of Onset; Aged; Amyloid beta-Peptides; Biomarkers; Humans; Lactates; Middle | 2020 |
Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study.
Topics: Aged; alpha-Synuclein; Biomarkers; Female; Humans; Longitudinal Studies; Male; Middle Aged; Parkinso | 2020 |
Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study.
Topics: Aged; Biomarkers; Caffeine; Case-Control Studies; Cross-Sectional Studies; Eating; Female; Humans; M | 2020 |
Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; U | 2020 |
Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson's Disease.
Topics: Aged; Cross-Sectional Studies; Fatigue; Female; Humans; Male; Middle Aged; Parkinson Disease; Prospe | 2020 |
Gender-specific effect of urate on white matter integrity in Parkinson's disease.
Topics: Aged; Diffusion Tensor Imaging; Female; Humans; Male; Middle Aged; Parkinson Disease; Sex Factors; U | 2020 |
Does Serum Urate Change as Parkinson's Disease Progresses?
Topics: Aged; Biomarkers; Corpus Striatum; Disease Progression; Dopamine Plasma Membrane Transport Proteins; | 2020 |
Peripheral Neuropathy in
Topics: Adult; Aged; Case-Control Studies; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Neural | 2020 |
Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study.
Topics: Aged; Biomarkers; Disease Progression; Female; Glucosylceramidase; Humans; Longitudinal Studies; Mal | 2021 |
Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
Topics: Aged; Biomarkers; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson | 2021 |
The association between multiple risk factors, clinical correlations and molecular insights in Parkinson's disease patients from Tamil Nadu population, India.
Topics: Adolescent; Adult; Aged; Cohort Studies; DNA, Mitochondrial; Dopamine; Environmental Exposure; Femal | 2021 |
Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression.
Topics: Disease Progression; Genome-Wide Association Study; Humans; Mendelian Randomization Analysis; Parkin | 2021 |
Low serum uric acid levels are associated with the nonmotor symptoms and brain gray matter volume in Parkinson's disease.
Topics: Apathy; Disease Progression; Gray Matter; Humans; Parkinson Disease; Uric Acid | 2022 |
Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype.
Topics: Adult; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Gait; Humans; | 2017 |
Dysregulation of serum NADPH oxidase1 and ferritin levels provides insights into diagnosis of Parkinson's disease.
Topics: Aged; Case-Control Studies; Female; Ferritins; Humans; Iran; Male; Middle Aged; NADP; NADPH Oxidases | 2017 |
Uric acid demonstrates neuroprotective effect on Parkinson's disease mice through Nrf2-ARE signaling pathway.
Topics: Animals; Antioxidant Response Elements; Behavior, Animal; Cognition; Cytokines; Hippocampus; Inflamm | 2017 |
3-Dimensional hollow graphene balls for voltammetric sensing of levodopa in the presence of uric acid.
Topics: Electrochemical Techniques; Electrodes; Graphite; Humans; Levodopa; Metal Nanoparticles; Nickel; Par | 2018 |
Gender-specific effect of uric acid on resting-state functional networks in de novo Parkinson's disease.
Topics: Aged; Cerebral Cortex; Connectome; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Ne | 2018 |
Urate and the risk of Parkinson's disease in men and women.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Female; | 2018 |
Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson's disease: PALS study.
Topics: Aged; Cohort Studies; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2018 |
Genetic variants related to urate and risk of Parkinson's disease.
Topics: Aged; Case-Control Studies; Cohort Studies; Female; Glucose Transport Proteins, Facilitative; Health | 2018 |
Level of uric acid and uric acid/creatinine ratios in correlation with stage of Parkinson disease.
Topics: Aged; Creatinine; Disease Progression; Dopamine; Female; Humans; Male; Parkinson Disease; Prognosis; | 2018 |
Mendelian randomization: Progressing towards understanding causality.
Topics: Genetic Variation; Humans; Mendelian Randomization Analysis; Parkinson Disease; Uric Acid | 2018 |
Plasma urate and risk of Parkinson's disease: A mendelian randomization study.
Topics: Aged; Biomarkers; Female; Follow-Up Studies; Genetic Variation; Humans; Male; Mendelian Randomizatio | 2018 |
Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's disease.
Topics: Biomarkers; Databases, Genetic; Genetic Variation; Humans; Mendelian Randomization Analysis; Parkins | 2018 |
Mendel and urate: Acid test or random noise?
Topics: Humans; Parkinson Disease; Polymorphism, Single Nucleotide; Risk Factors; Uric Acid | 2018 |
Serum uric acid and albumin are affected by different variables in Parkinson's disease.
Topics: Biomarkers; Humans; Parkinson Disease; Purines; Serum Albumin; Uric Acid | 2019 |
Higher urate in LRRK2 mutation carriers resistant to Parkinson disease.
Topics: Adult; Aged; Biomarkers; Cohort Studies; Disease Resistance; Female; Genetic Predisposition to Disea | 2019 |
Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson's Disease.
Topics: Aged; Case-Control Studies; Cognitive Dysfunction; Disease Progression; Female; Follow-Up Studies; H | 2019 |
Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers".
Topics: DNA, Mitochondrial; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkins | 2019 |
Mitochondrial DNA Deletions Discriminate Affected from Unaffected LRRK2 Mutation Carriers.
Topics: DNA, Mitochondrial; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkins | 2019 |
Gout and the risk of Parkinson's disease in Denmark.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Denmark; Drug Prescriptions; Female; Gout; Gou | 2013 |
Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Brain; Case-Control Studies; Femal | 2013 |
Plasma urate in REM sleep behavior disorder.
Topics: Female; Humans; Linear Models; Male; Parkinson Disease; Polysomnography; REM Sleep Behavior Disorder | 2013 |
Genetic variability related to serum uric acid concentration and risk of Parkinson's disease.
Topics: Aged; Alleles; Disease Progression; Female; Genetic Predisposition to Disease; Genetic Variation; Ge | 2013 |
Identification of key uric acid synthesis pathway in a unique mutant silkworm Bombyx mori model of Parkinson's disease.
Topics: Animals; Bombyx; Disease Models, Animal; Mutation; Oxidative Stress; Parkinson Disease; Signal Trans | 2013 |
Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allopurinol; Animals; | 2013 |
Serum uric acid and risk of dementia in Parkinson's disease.
Topics: Aged; Dementia; DNA Mutational Analysis; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; | 2014 |
Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease.
Topics: Allopurinol; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Enzym | 2014 |
Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Male; Men | 2014 |
Novel biosensor may be an important step towards diagnosing early-stage Parkinson's disease.
Topics: Ascorbic Acid; Biosensing Techniques; Dopamine; Electrodes; Graphite; Humans; Nanowires; Parkinson D | 2014 |
Serum uric acid concentration is linked to wearing-off fluctuation in Japanese Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Disease Progression; Female; Humans; Japan; Male; Midd | 2014 |
Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease.
Topics: Adult; Aged; Biomarkers; Disease Progression; Female; Humans; Male; Middle Aged; Parkinson Disease; | 2015 |
Synthesis of short graphene oxide nanoribbons for improved biomarker detection of Parkinson's disease.
Topics: Ascorbic Acid; Biomarkers; Biosensing Techniques; Dopamine; Graphite; Humans; Nanotubes, Carbon; Oxi | 2015 |
Uric acid relates to dopamine transporter availability in Parkinson's disease.
Topics: Adult; Aged; Biomarkers; Dopamine Plasma Membrane Transport Proteins; Early Diagnosis; Female; Human | 2015 |
Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study.
Topics: Female; Humans; Iron; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Pilot Projec | 2014 |
[Cognitive dysfuctions associated with essential tremor and Parkinson's disease].
Topics: Cognition; Cognition Disorders; Depression; Depressive Disorder; Essential Tremor; Humans; Language; | 2014 |
Lower Serum Bilirubin and Uric Acid Concentrations in Patients with Parkinson's Disease in China.
Topics: Aged; Aged, 80 and over; Antioxidants; Asian People; Bilirubin; Case-Control Studies; China; Dopamin | 2015 |
Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies.
Topics: Adult; Aged; Databases, Factual; England; Female; Gout; Hospitalization; Humans; Male; Middle Aged; | 2015 |
Association between serum uric acid and motor subtypes of Parkinson's disease.
Topics: Aged; Antioxidants; Biomarkers; Creatinine; Disease Progression; Female; Humans; Male; Middle Aged; | 2015 |
Genome-wide variant by serum urate interaction in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Behavior; Corpus Striatum; Disease Progression; Dopamine; Dopamine P | 2015 |
Low serum uric acid levels in progressive supranuclear palsy.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Multiple System | 2016 |
Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease.
Topics: Aged; Apathy; Biomarkers; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Dis | 2016 |
Potential mechanisms for low uric acid in Parkinson disease.
Topics: Aged; Aged, 80 and over; Allantoin; Female; Humans; Male; Middle Aged; Parkinson Disease; Uric Acid | 2016 |
The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Disease Progression; Female; Humans; Levodopa; Log | 2016 |
Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease.
Topics: Antioxidants; Disease Progression; Female; Humans; Inosine; Male; Middle Aged; Oxidative Stress; Par | 2016 |
Bilirubin and Uric Acid: Two Different Anti-oxidants in Parkinson's Disease.
Topics: Antioxidants; Bilirubin; Disease Progression; Humans; Parkinson Disease; Uric Acid | 2016 |
Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study.
Topics: Aged; Cognitive Dysfunction; Female; Humans; Italy; Logistic Models; Longitudinal Studies; Magnetic | 2016 |
Impact of serum uric acid, albumin and their interaction on Parkinson's disease.
Topics: Aged; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Parkinson Disease; Risk Factors; S | 2017 |
Serum uric acid levels in Parkinson's disease and related disorders.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Multiple System | 2017 |
Serum uric acid levels and freezing of gait in Parkinson's disease.
Topics: Antiparkinson Agents; Biomarkers; Body Mass Index; Cognition; Cross-Sectional Studies; Disease Progr | 2017 |
Serum uric acid and clinical progression in Parkinson disease: potential biomarker for nigrostriatal failure.
Topics: Biomarkers; Corpus Striatum; Disease Progression; Humans; Parkinson Disease; Randomized Controlled T | 2008 |
Re: Gout and risk of Parkinson disease: a prospective study.
Topics: Comorbidity; Databases as Topic; Diagnostic Errors; Epidemiologic Studies; Gout; Humans; Parkinson D | 2008 |
Re: Gout and risk of Parkinson disease: a prospective study.
Topics: Comorbidity; Dose-Response Relationship, Drug; Free Radical Scavengers; Gout; Gout Suppressants; Hum | 2008 |
Gout and the risk of Parkinson's disease: a cohort study.
Topics: Aged; Aged, 80 and over; Antioxidants; British Columbia; Case-Control Studies; Cohort Studies; Diure | 2008 |
Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study.
Topics: Antiparkinson Agents; Atherosclerosis; Biomarkers; Black or African American; Cohort Studies; Commun | 2009 |
Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Female; Humans; Levodopa; Male; Middle Aged; Parkinson | 2009 |
Metabolomic profiling in LRRK2-related Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Gene Expression Regulation; Humans; Hypoxanthine | 2009 |
Medication trials in an imperfect world: gout and Parkinson's disease.
Topics: Antiparkinson Agents; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug-R | 2009 |
Natural oxidant balance in Parkinson disease.
Topics: Biomarkers; Humans; Oxidants; Parkinson Disease; Uric Acid | 2009 |
Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Male; Middle Ag | 2010 |
Potential role of uric acid as a biomarker for Parkinson's disease.
Topics: Biomarkers; Humans; Models, Biological; Parkinson Disease; Risk; Uric Acid | 2010 |
Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease.
Topics: Age of Onset; Alleles; Female; Glucose Transport Proteins, Facilitative; Humans; Male; Parkinson Dis | 2011 |
Plasma urate and Parkinson's disease in women.
Topics: Adult; Age Factors; Alcohol Drinking; Body Mass Index; Diet; Exercise; Female; Health Status; Hormon | 2010 |
Biomarkers in Parkinson's disease: a funder's perspective.
Topics: alpha-Synuclein; Biomarkers; Carrier Proteins; Cytokines; Glutathione; Humans; Intracellular Signali | 2010 |
Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: changes linked to disease progression.
Topics: Aged; Aryldialkylphosphatase; Disease Progression; Female; Ferritins; Humans; Lipids; Male; Oxidativ | 2011 |
Uric acid and cognition in Parkinson's disease: a follow-up study.
Topics: Aged; Cognition Disorders; Cross-Sectional Studies; Female; Humans; Longitudinal Studies; Male; Ment | 2011 |
Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".
Topics: Adult; Aged; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Male; Middle Age | 2011 |
The risk of Parkinson disease associated with urate in a community-based cohort of older adults.
Topics: Aged; California; Cohort Studies; Female; Humans; Male; Maryland; North Carolina; Parkinson Disease; | 2011 |
Lower serum UA levels in Parkinson's disease patients in the Chinese population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Biomarkers; China; Disease Progression; Fe | 2012 |
Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients.
Topics: Aged; Case-Control Studies; Female; Humans; Male; Middle Aged; Parkinson Disease; Uric Acid | 2012 |
Low serum uric acid concentration in Parkinson's disease in southern Spain.
Topics: Female; Humans; Male; Parkinson Disease; Spain; Uric Acid | 2013 |
Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cross-Sectional Studies; Female; Humans; Male; Middle Ag | 2013 |
Serum uric acid in patients with Parkinson's disease and vascular parkinsonism: a cross-sectional study.
Topics: Biomarkers; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Parkinson Disease; Uric Acid | 2013 |
Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.
Topics: Aged; Antioxidants; Glutathione; Humans; Multiple System Atrophy; Oxidative Stress; Parkinson Diseas | 2003 |
Dopamine and uric acid act as antioxidants in the repair of DNA radicals: implications in Parkinson's disease.
Topics: Animals; Antioxidants; Brain; DNA; DNA Damage; DNA Repair; Dopamine; Dose-Response Relationship, Rad | 2003 |
The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apomorphine; Aspirin; Brain; Catalysis; Cell Line, Tumor; Dogs | 2004 |
Serum uric acid levels and the risk of Parkinson disease.
Topics: Aged; Aged, 80 and over; Community Health Planning; Confidence Intervals; Female; Follow-Up Studies; | 2005 |
Low plasma uric acid level in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Energy Intake; Female; Ferritins; Humans; Levodopa; Mal | 2007 |
Plasma urate and risk of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Humans; Incidence; Logistic Models | 2007 |
Metabolomic profiling to develop blood biomarkers for Parkinson's disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Antiparkinson Agents; Biomarkers; Chromatography, High Pressure | 2008 |
Re: "plasma urate and risk of Parkinson's disease".
Topics: Biomarkers; Humans; Oxidative Stress; Parkinson Disease; Risk Factors; Uric Acid | 2008 |
Uric acid associates with cognition in Parkinson's disease.
Topics: Choice Behavior; Cognition Disorders; Female; Humans; Linear Models; Male; Memory; Neuropsychologica | 2008 |
Diet, urate, and Parkinson's disease risk in men.
Topics: Adult; Aged; Diet; Humans; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Prospe | 2008 |
Interference of levodopa and its metabolites with colorimetry of uric acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Colorimetry; Dopamine; Homovanillic Acid; Humans; Levodopa; Parkinso | 1981 |
The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease.
Topics: Aged; Alzheimer Disease; Dementia, Multi-Infarct; Dementia, Vascular; Humans; Parkinson Disease; Psy | 1993 |
Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation.
Topics: Aged; Ascorbic Acid; Brain Chemistry; Dopamine; Female; Humans; Male; Nerve Degeneration; Neural Pat | 1994 |
Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease.
Topics: Aged; Confounding Factors, Epidemiologic; Follow-Up Studies; Hawaii; Humans; Incidence; Male; Middle | 1996 |
Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Ascorbic Acid; Chlorides; Chromatography, H | 2000 |
Purine-induced alterations of dopamine metabolism in rat pheochromocytoma PC12 cells.
Topics: Adenine; Adenosine; Animals; Disease Models, Animal; Dopamine; Guanine; Guanosine; Hypoxanthine; Neo | 2000 |
Decreased renal clearance of xanthine and hypoxanthine in a patient with renal hypouricemia: a new defect in renal handling of purines.
Topics: Humans; Hypoxanthine; Hypoxanthines; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; P | 1992 |
[Arthritis urica and L-dopa therapy].
Topics: Dihydroxyphenylalanine; Gout; Humans; Parkinson Disease; Uric Acid | 1973 |
Gout while receiving levodopa for Parkinsonism.
Topics: Aged; Dihydroxyphenylalanine; Gout; Humans; Male; Middle Aged; Parkinson Disease; Uric Acid | 1972 |
Hyperuricemia and levodopa.
Topics: Dihydroxyphenylalanine; Gout; Humans; Parkinson Disease; Uric Acid | 1971 |
Hyperuricemia and levodopa.
Topics: Aged; Dihydroxyphenylalanine; Female; Gout; Humans; Male; Parkinson Disease; Uric Acid | 1971 |